All Posts Tagged With: "OREX"
(OREX) Orexigen Therapeutics Lifeline for Contrave
Orexigen Therapeutics, Inc.‘s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration’s (FDA) office of new drugs (OND) regarding the development path...
(ACM) Company News for June 02, 2011 – Corporate Summary
• Shares of H.J. Heinz Co (NYSE:HNZ) were downgraded by Goldman Sachs (NYSE:GS) from “Neutral” rating to “Sell” rating and its target price...
(VVUS) Vivus First Quarter 2011 Loss Narrower than Expected
Vivus Inc.’s (VVUS) first quarter 2011 loss of 12 cents per share was narrower than the Zacks Consensus loss Estimate by 3 cents and the year-ago loss (from continuing operations) by 9 cents. The narrower...
(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration
Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present...
(VVUS) Vivus Seeks EU Nod for Qnexa
Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa...
(ARNA) Arena Pharmaceuticals is Denied FDA Approval for Obesity Candidate Drug
The US Food and Drug Administration (FDA) dealt a major blow to Arena Pharmaceuticals (ARNA) by refusing to approve the company’s obesity candidate lorcaserin citing tumor-related safety concerns. The US...
(ABT) Abbott Labs Removes Obesity Drug Meridia From Market
Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs’ decision was based on a request made by the US Food and Drug Administration (FDA).
The...
(VVUS) FDA to Review Vivus Drug
The US Food and Drug Administration (FDA) recently posted briefing documents on its website ahead of the review of Vivus’ (VVUS) obesity drug Qnexa by the FDA’s Endocrinologic & Metabolic Drugs Advisory...
(VVUS) VIVUS Obesity Drug Application for Qnexa to Get FDA Review
Recently, VIVUS, Inc. (VVUS) announced that the New Drug Application (NDA) for its obesity candidate, Qnexa, will be reviewed by the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food...
(AMLN) Amylin Pharmaceuticals’ Obesity Drug Pipeline Advances
Amylin Pharmaceuticals, Inc. (AMLN) and partner Takeda Pharmaceutical Company Limited recently announced that they intend to advance their obesity combination treatment of pramlintide and metreleptin into...
(MRK) Merck & Co Ends Deal with Arena Pharmaceuticals
Merck & Co (MRK) recently informed its partner Arena Pharmaceuticals (ARNA) that it was pulling out of a collaboration agreement pertaining...
(ARNA) Amylin Pharmaceuticals Strikes First on Obesity
Almost all of the news in the obesity race has been made recently by three small biotech companies — Arena Pharmaceuticals (ARNA), Vivus Inc. (
2Nov2009 | vitalstocks | 0 comments | Continued(ARNA) Arena Pharmaceuticals’ Lorcaserin Has Safety Edge
Results from Arena Pharmaceuticals’ (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated...